<SEC-DOCUMENT>0001558370-25-006602.txt : 20250507
<SEC-HEADER>0001558370-25-006602.hdr.sgml : 20250507
<ACCEPTANCE-DATETIME>20250507070140
ACCESSION NUMBER:		0001558370-25-006602
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250507
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250507
DATE AS OF CHANGE:		20250507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RHYTHM PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001649904
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				462159271
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38223
		FILM NUMBER:		25919223

	BUSINESS ADDRESS:	
		STREET 1:		222 BERKELEY STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		857-264-4280

	MAIL ADDRESS:	
		STREET 1:		222 BERKELEY STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RHYTHM METABOLIC, INC.
		DATE OF NAME CHANGE:	20150803
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rytm-20250507x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.10.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 5/6/2025 10:11:46 PM -->
<!-- iXBRL Library version: 1.0.9179.3415 -->
<!-- iXBRL Service Job ID: 151f8b83-3b16-48f4-b810-cad0a786c498 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:rytm="http://www.rhythmtx.com/20250507" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" name="dei:EntityCentralIndexKey" id="Tc_9O_02z6gHEm9BfBTDa9u5A_2_1">0001649904</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" name="dei:AmendmentFlag" id="Tc_7qKdcS9CbECfe8iwelMl4A_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="rytm-20250507.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649904</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-07</xbrli:startDate><xbrli:endDate>2025-05-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_cfaf520f_4cea_42a3_ad87_e83b493acced"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" name="dei:DocumentType" id="Narr_z6QW5g85E0Ky2mZQZjkEOQ"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section 13 or 15(d)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">of <b style="font-weight:bold;">the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_5_ltw3aXGkeUdfohllrkng">May 7, 2025</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" name="dei:EntityRegistrantName" id="Narr_BXS1KV24KE6SkUEVGzq01g"><b style="font-weight:bold;">RHYTHM PHARMACEUTICALS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_1950036c_3314_4a24_a5b6_c0d127cd7be0"></a><a id="Tc_oGLGDMxLMkyRc627AlvGFg_1_0"></a><a id="Tc_vY4WAzDQz0mUH13LPQHwkA_1_2"></a><a id="Tc_hOZPbd7yek2D7In4P4LTPg_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:36.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_mcdMqPCO4k-zhT0dbLySvQ_0_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:23.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" name="dei:EntityFileNumber" id="Tc_jmZNy_5G506ze2wRHzg7dw_0_2"><b style="font-weight:bold;">001-38223</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:35.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" name="dei:EntityTaxIdentificationNumber" id="Tc_wdOEX_W7QkCwqtrVPLGZMA_0_4"><b style="font-weight:bold;">46-2159271</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:36.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(State or other jurisdiction<br/>of incorporation)</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Commission<br/>File Number)</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:35.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(IRS Employer<br/>Identification Number)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" name="dei:EntityAddressAddressLine1" id="Narr_j00hizaKnUmellr58-p8Gg"><b style="font-weight:bold;">222 Berkeley Street</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" name="dei:EntityAddressAddressLine2" id="Narr_vc6HyEUYGkO1E9t8o0LFvw"><b style="font-weight:bold;">12th Floor</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" name="dei:EntityAddressCityOrTown" id="Narr_IqbhZqGIq0G5KtCai2l_MA"><b style="font-weight:bold;">Boston</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" name="dei:EntityAddressStateOrProvince" id="Narr_UQQTdYDXWk6WHZjnS7y6GA"><b style="font-weight:bold;">MA</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" name="dei:EntityAddressPostalZipCode" id="Narr_zTNLCF3dxEW8ylSItbB0wQ"><b style="font-weight:bold;">02116</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Address of principal executive offices) (Zip Code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Registrant&#8217;s telephone number, including area code: <b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" name="dei:CityAreaCode" id="Narr_5taFRDHsHkaHsnhiqQZ0qA"><b style="font-weight:bold;">857</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" name="dei:LocalPhoneNumber" id="Narr_73wo20p600Kx6cAN-J_3UQ"><b style="font-weight:bold;">264-4280</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Former name or former address, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_NUr9-ew96k2vEh-S1nGJYQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_1WwEAAvvLU2drqMjL8fXMg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_vDhae_m_e0u7dgMUGZdCqg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_eYC4BXG_BUWWcIsa0sGkDA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_634a9b10_b673_413d_bf85_ba9d97ef0808"></a><a id="Tc_F3lJUPJ1VUy2y-vFobABeQ_0_0"></a><a id="Tc_C2oUOkDChkGqR1D442eGvQ_0_1"></a><a id="Tc_HaOSCwBdpU-FglvztnMHJQ_0_2"></a><a id="Tc_H-aiCYJNA0yHSn2ylFzevQ_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:40.7%;border-bottom:1px solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 2.75pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:10.35%;border-bottom:1px solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 2.75pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Trading<br/>Symbol(s)</p></td><td style="vertical-align:bottom;width:48.93%;border-bottom:1px solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:40.7%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.75pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" name="dei:Security12bTitle" id="Tc_K1YPFtmv_0qgTH83a6INyA_1_0">Common Stock, $0.001 par value per share</ix:nonNumeric></p></td><td style="vertical-align:top;width:10.35%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 2.75pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" name="dei:TradingSymbol" id="Tc_ao2ncnMTOUex6aPLvWYFGQ_1_1">RYTM</ix:nonNumeric></p></td><td style="vertical-align:top;width:48.93%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Narr_lV8hFqhSO0OD8_VT6jQBuA">The Nasdaq Stock Market LLC</ix:nonNumeric> (Nasdaq Global Market)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_iWD5zC-oGE-6sEAzhuum9Q"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b66938b0_ef6b_4b19_98d2_bb8d642356c1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 2.02. Results of Operations and Financial Condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May 7, 2025, Rhythm Pharmaceuticals, Inc. (the &#8220;Company&#8221;) announced its financial results for the first quarter ended March 31, 2025. The full text of the press release issued by the Company in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the &#8220;Current Report&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information contained in Item 2.02 of this Current Report (including Exhibit 99.1 attached hereto) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act, except as expressly provided by specific reference in such a filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_262b6037_485a_46c7_80d6_fe96eac5c4f1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 9.01. Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(d) Exhibits</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following Exhibit 99.1 relates to Item 2.02 and shall be deemed to be furnished, and not filed:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:87.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:10.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br/><b style="font-weight:bold;">No.</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:87.86%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:middle;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="rytm-20250507xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press release dated May 7, 2025</span></a></p></td></tr><tr><td style="vertical-align:middle;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:middle;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:87.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (embedded within the inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_8b807687_8b66_4d26_9940_9cb2f5402b56"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:46.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:51.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">RHYTHM PHARMACEUTICALS, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 7, 2025</p></td><td style="vertical-align:top;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.21%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Hunter Smith</p></td></tr><tr><td style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hunter Smith</p></td></tr><tr><td style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>rytm-20250507xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 5/6/2025 10:11:44 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">EXHIBIT 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;line-height:1.37;margin-bottom:10pt;text-decoration-color:#000000;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:italic;line-height:1.37;margin-bottom:10pt;text-decoration-color:#000000;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">-- First quarter 2025 net product revenue from global sales of IMCIVREE</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:8.25pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#160;(setmelanotide) of&#160;$37.7 million&#160; --</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:italic;line-height:1.37;margin-bottom:10pt;text-decoration-color:#000000;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">-- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity -- </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;line-height:1.37;margin-bottom:10pt;text-decoration-color:#000000;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;padding-bottom:0pt;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">-- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 </i><i style="color:#2f2f2f;font-family:'Arial','Helvetica','sans-serif';font-style:italic;background:#ffffff;">--</i><i style="color:#2f2f2f;font-family:'Open Sans';font-style:italic;white-space:pre-wrap;background:#ffffff;">  </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;line-height:1.37;margin-bottom:10pt;text-decoration-color:#000000;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">-- Topline data from Phase 2 trial of oral MC4R agonist bivamelagon on track to be announced in third quarter of 2025 -- </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;line-height:1.37;margin-bottom:10pt;text-decoration-color:#000000;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;white-space:pre-wrap;">-- Cash on-hand expected to support planned operations into 2027 --   </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;line-height:1.37;margin-bottom:10pt;text-decoration-color:#000000;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">-- Management to host conference call today at 8:00</i><font style="font-family:'Arial','Helvetica','sans-serif';"> </font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">a.m. ET --</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;line-height:1.37;margin-bottom:10pt;text-decoration-color:#000000;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">BOSTON, May 7, 2025 &#8211; </b><font style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;">Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today reported financial results and provided a business update for the first quarter ended March 31, 2025.    </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';line-height:1.37;margin-bottom:10pt;text-decoration-color:#000000;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;Following compelling topline results from our pivotal Phase 3 trial of setmelanotide in acquired hypothalamic obesity (HO), we look forward to completing U.S. and EU regulatory submissions in the third quarter of 2025 and, pending approval, bringing the first-ever known approved therapy for this serious disease to patients,&#8221; said David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm.</font> &#8220;<font style="font-family:'Arial','Helvetica','sans-serif';">In addition, we are advancing our next-generation MC4R agonists as we are on track to read out topline data from the Phase 2 trial evaluating the oral-daily bivamelagon in patients with HO in the third quarter of 2025.&#8221; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';line-height:1.37;margin-bottom:10pt;text-decoration-color:#000000;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Dr. Meeker continued, &#8220;With BBS, we are pleased with the continued growth in the number of patients on reimbursed therapy with a steady increase in new physicians writing prescriptions in the United States along with the ongoing strong performance internationally. In addition, we believe Rhythm is well capitalized with a cash runway into 2027, beyond multiple clinical and regulatory milestones expected this year and early next year.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';line-height:1.37;margin-bottom:10pt;text-decoration-color:#000000;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;background:#ffffff;">First Quarter and Recent Business Highlights</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;font-weight:bold;line-height:1.37;margin-bottom:10pt;text-decoration-color:#000000;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Revenue from global sales of </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">IMCIVREE</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">&#160;(setmelanotide)</font><i style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:italic;font-weight:normal;"> </i><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">was $37.7 million for the first quarter of 2025. The number of patients on reimbursed therapy increased 14% in the first quarter of 2025 compared to the fourth quarter of 2024, as patient demand for IMCIVREE remained strong. Revenue of $24.5 million, or 65% of product revenue, was generated in the United States. The number of patients on reimbursed therapy in the United States continued to increase during the quarter. U.S. revenue was affected by an $8.3 million decrease in inventory at the specialty pharmacy that dispenses IMCIVREE to patients and a $1.1 million increase in product dispensed to patients, resulting in a net </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">decrease in U.S. product revenue of $7.2 million in the first quarter of 2025 compared to the fourth quarter of 2024. Revenue of $13.2 million, or 35% of product revenue, was generated outside the United States, an increase of $3.2 million quarter over quarter.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">On April 7, 2025, Rhythm announced its pivotal Phase 3 TRANSCEND trial met its primary endpoint with a -19.8% placebo-adjusted body mass index (BMI) reduction with setmelanotide in patients (N=120) with acquired HO; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">Patients with acquired HO on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks (p&lt;0.0001);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">-19.2% placebo-adjusted BMI reduction achieved in adult patients 18 years old and older (n=49) at 52 weeks;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">-20.2% placebo-adjusted BMI reduction achieved in patients younger than 18 years old (n=71) at 52 weeks;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">80% of patients on setmelanotide achieved BMI reduction of 5% or greater at 52 weeks; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">No new safety signals with setmelanotide were observed, in line with setmelanotide&#8217;s well-established and well-understood safety profile.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">Today, Rhythm announced new data from the Phase 3 TRANSCEND trial that demonstrated a consistent and statistically significant mean BMI reduction across three stratified age groups: </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;background:#ffffff;"> -19.5% placebo-adjusted BMI reduction achieved in pediatric patients ages 4 to younger than 12 years old (n=31: 20 setmelanotide, 11 placebo) at 52 weeks (p&lt;0.0001);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">-21.0% placebo-adjusted BMI reduction achieved in adolescent patients ages 12 to younger than 18 years old (n=40: 28 setmelanotide, 12 placebo) at 52 weeks (p&lt;0.0001); and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">-19.2% placebo-adjusted BMI reduction achieved in adult patients ages 18 and older (n=49: 33 setmelanotide, 16 placebo) at 52 weeks (p&lt;0.0001). </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">On April 7, 2025, Rhythm </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">announced it dosed the first patients with Prader-Willi syndrome in a 26-week, open-label Phase 2 trial of setmelanotide. The trial will assess the safety and efficacy of a daily dose of subcutaneous setmelanotide in approximately 20 patients for up to 26 weeks;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">On March 20, 2025, Rhythm announced it reacquired the rights to IMCIVREE</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:8.25pt;font-style:normal;font-weight:normal;vertical-align:top;background:#ffffff;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;"> in China, including mainland China, Hong Kong and Macau, as the Company agreed to terminate its 2021 licensing agreement with RareStone Group Ltd.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">On March 19, 2025, </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">Rhythm </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">announced it received orphan drug designation from Japan&#8217;s Ministry of Health, Labour and Welfare (MHLW) for setmelanotide as a treatment for acquired hypothalamic obesity; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">On March 18, 2025, Rhythm announced a new research collaboration with the Raymond A. Wood Foundation, a patient advocacy organization for survivors of craniopharyngioma and hypothalamic-pituitary brain tumors, to study the impact of fatigue on persons with craniopharyngioma.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="color:#2f2f2f;font-family:'Arial','Helvetica','sans-serif';line-height:1.37;margin-bottom:10pt;margin-left:0pt;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Anticipated Upcoming Milestones</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;font-weight:bold;line-height:1.37;margin-bottom:10pt;text-decoration-color:#000000;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Rhythm expects to achieve the following near-term milestones: </font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency for setmelanotide for the treatment of acquired HO in the third quarter of 2025;</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Announce topline data from the bivamelagon Phase 2 trial in acquired HO in the third quarter of 2025;  </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Complete enrollment in the setmelanotide Phase 2 trial in Prader-Willi syndrome (PWS) in the second half of 2025;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Complete enrollment in the Phase 1, Part C trial evaluating the weekly, MC4R agonist RM-718 in patients with acquired hypothalamic obesity in the second half of 2025;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Complete enrollment in the setmelanotide Phase 3 trial substudy in congenital hypothalamic obesity in the second half of 2025; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Announce topline data in the 12-patient Japanese cohort of the setmelanotide Phase 3 trial in acquired HO in the first quarter of 2026; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Announce topline data in the Phase 3 EMANATE trial evaluating setmelanotide in genetically caused MC4R pathway diseases in the first quarter of 2026.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">First Quarter 2025 Financial Results:</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Cash Position:</b> As of March 31, 2025, cash, cash equivalents and short-term investments were approximately $314.5 million, as compared to $320.6 million as of December 31, 2024. </p><p style="border-top-style:none;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Revenue:</b> Net product revenues relating to global sales of IMCIVREE were $37.7 million for the first quarter of 2025, as compared to $26.0 million for the first quarter of 2024. License revenue for the first quarter of 2025 was ($5.0) million, a reduction entirely due to the termination of an exclusive license agreement with RareStone Group Ltd. and the repayment by Rhythm of a portion of previously-recognized license revenue. </p><p style="border-top-style:none;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">R&amp;D Expenses:</b> R&amp;D expenses were $37.0 million in the first quarter of 2025, as compared to $128.7 million in the first quarter of 2024. The decrease was primarily due to the R&amp;D expenses incurred in the first quarter of 2024 related to in-process research and development costs totaling $92.4 million associated with the acquisition of LG Chem&#8217;s proprietary compound bivamelagon, which did not recur in 2025.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">SG&amp;A Expenses:</b> SG&amp;A expenses were $39.1 million for the first quarter of 2025, as compared to $34.4 million for the first quarter of 2024. The year-over-year increase was primarily due to increased headcount and an increase in marketing to support continued revenue growth.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Other expense, net:</b> Other expense, net was $2.4 million for the first quarter of 2025, as compared to other expense, net of $1.2 million for the first quarter of 2024.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Net Loss:</b> Net loss attributable to common stockholders was ($50.8) million for the first quarter of 2025, or a net loss per basic and diluted share of ($0.81), as compared to a net loss attributable to common stockholders of ($141.4) million for the first quarter of 2024, or a net loss per basic and diluted share of ($2.35).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Financial Guidance:</b> For the year ending December 31, 2025, Rhythm anticipates approximately $285 million to $315 million in Non-GAAP Operating Expenses. Non-GAAP Operating Expenses are derived from:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">GAAP total operating expenses, inclusive of:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">SG&amp;A expenses of approximately $135 million to $145 million;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">R&amp;D expenses of approximately $150 million to $170 million; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Excluding stock-based compensation.</font></td></tr></table><div style="margin-top:18pt;"></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">Non-GAAP Operating Expenses is defined as GAAP operating expenses excluding stock-based compensation and fixed consideration related to in-licensing (see below under &quot;Non-GAAP Financial Measures&quot; for more details).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">Based on its current operating plans, Rhythm expects that its existing cash, cash equivalents and short-term investments as of March 31, 2025, will be sufficient to fund its operating expenses and capital expenditure requirements into 2027.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Conference Call Information</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET today to review its first quarter 2025 financial results and recent business activities. Participants may register for the conference call here. It is recommended that participants join the call ten minutes prior to the scheduled start.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">A webcast of the call will also be available under &quot;Events and Presentations&quot; in the Investor Relations section of the Rhythm Pharmaceuticals website at https://ir.rhythmtx.com/. The archived webcast will be available on Rhythm Pharmaceuticals&#8217; website approximately two hours after the conference call and will be available for 30 days following the call.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">About Rhythm Pharmaceuticals</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm&#8217;s lead asset, IMCIVREE<sup style="font-size:8.25pt;vertical-align:top;">&#174;</sup> (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. Both the European Commission (EC) and the UK&#8217;s Medicines &amp; Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm&#8217;s headquarters is in Boston, MA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Setmelanotide Indication</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">In the United States, setmelanotide is indicated to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">In the European Union and the United Kingdom, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. In the European Union and the United Kingdom, setmelanotide should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Limitations of Use</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 12pt 0pt;">Setmelanotide is <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">not</u> indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Obesity due to suspected POMC, PCSK1, or LEPR deficiency with </font><i style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;">POMC</i><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><i style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;">PCSK1</i><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">, or</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;"><i style="font-style:italic;">LEPR </i>variants classified as benign or likely benign</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Contraindication</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 12pt 0pt;">Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WARNINGS AND PRECAUTIONS</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Disturbance in Sexual Arousal: </b>Spontaneous penile erections in males and sexual adverse reactions in females have occurred. Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Depression and Suicidal Ideation: </b>Depression, suicidal ideation and depressed mood have occurred. Monitor patients for new onset or worsening depression or suicidal thoughts or behaviors. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Hypersensitivity Reactions: </b>Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue IMCIVREE.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Skin Hyperpigmentation, Darkening of Pre-existing Nevi, and Development of New Melanocytic Nevi: </b>Generalized or focal increases in skin pigmentation, darkening of pre-existing nevi, development of new melanocytic nevi and increase in size of existing melanocytic nevi have occurred. Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new pigmented lesions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates and Low Birth Weight Infants: </b>IMCIVREE is not approved for use in neonates or infants. Serious and fatal adverse reactions including &#8220;gasping syndrome&#8221; can occur in neonates and low birth weight infants treated with benzyl alcohol preserved drugs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ADVERSE REACTIONS</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 12pt 0pt;">Most common adverse reactions (incidence &#8805;20%) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">USE IN SPECIFIC POPULATIONS</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 12pt 0pt;">Treatment with IMCIVREE is not recommended when breastfeeding. Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 12pt 0pt;">To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or <u style="color:#0563c1;text-decoration-color:#0563c1;text-decoration-line:underline;text-decoration-style:solid;">www.fda.gov/medwatch</u>. See section 4.8 of the Summary of Product Characteristics  for information on reporting suspected adverse reactions in Europe.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;margin:0pt;"><b style="color:#333333;font-weight:bold;">Please see the full Prescribing Information for additional Important Safety Information.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the safety, efficacy, potential benefits of, and clinical design or progress of any of our products or product candidates at any dosage or in any indication, including, setmelanotide, bivamelagon, and RM-718; the potential use of setmelanotide in patients with acquired hypothalamic obesity; the commercial growth of IMCIVREE; our expectations surrounding potential regulatory submissions, progress, or approvals and timing thereof for any of our product candidates,<font style="font-size:12pt;"> </font>including the anticipated supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency; the estimated market size and addressable population for our drug products, including setmelanotide for the treatment of hypothalamic obesity; the future announcement of data from our ongoing clinical trials, including the Japanese cohort of our Phase 3 trial evaluating setmelanotide for patients with acquired hypothalamic obesity, the substudy evaluating setmelanotide for patients with congenital hypothalamic obesity, the Phase 3 EMANATE trial evaluating setmelanotide in genetically caused MC4R pathway diseases, and the Phase 2 trial evaluating the oral MC4R agonist bivamelagon in acquired hypothalamic obesity; Part C of the Phase 1 trial evaluating RM-718; the open-label Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome; the ongoing enrollment in our clinical trials; the Company&#8217;s business strategy and plans; our anticipated financial performance and financial position for any period of time, including estimated Non-GAAP Operating Expenses for the year ending December 31, 2025; and the sufficiency of our cash, cash equivalents and short-term investments to fund our operations; and the timing of any of the foregoing. Statements using words such as &#8220;expect&#8221;, &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;may&#8221;, &#8220;will&#8221;, &#8220;aim&#8221; and similar terms are also forward-looking statements. Such statements are subject to numerous risks and uncertainties, including, but not limited to, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the ability to achieve necessary regulatory approvals, risks associated with data analysis and reporting, failure to identify and develop additional product candidates, unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, risks associated with the laws and regulations governing our international operations and the costs of any related compliance programs, the impact of competition, risks relating to product liability lawsuits, inability to maintain collaborations, or the failure of these collaborations, our reliance on third parties, risks relating to intellectual property, our ability to hire and retain necessary personnel, general economic conditions, risks related to internal control over financial reporting, and the other important factors discussed under the caption &#8220;Risk Factors&#8221; in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 and our other filings with the Securities and Exchange Commission. Except as required by law, we </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:18pt;background:#ffffff;margin:0pt;">undertake no obligations to make any revisions to the forward-looking statements contained in this press release or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Non-GAAP Financial Measures</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">This press release includes Non-GAAP Operating Expenses, a supplemental measure of our performance that is not required by, or presented in accordance with, U.S. GAAP and should not be considered as an alternative to operating expenses or any other performance measure derived in accordance with GAAP.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">We define Non-GAAP Operating Expenses as GAAP operating expenses excluding stock-based compensation and fixed consideration related to in-licensing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">We caution investors that amounts presented in accordance with our definition of Non-GAAP Operating Expenses may not be comparable to similar measures disclosed by our competitors because not all companies and analysts calculate this non-GAAP financial measure in the same manner. We present this non-GAAP financial measure because we consider it to be an important supplemental measure of our performance and believe it is frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in our industry. Management believes that investors&#8217; understanding of our performance is enhanced by including this non-GAAP financial measure as a reasonable basis for comparing our ongoing results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">Management uses this non-GAAP financial measure for planning purposes, including the preparation of our internal annual operating budget and financial projections; to evaluate the performance and effectiveness of our operational strategies; and to evaluate our capacity to expand our business. This non-GAAP financial measure has limitations as an analytical tool, and should not be considered in isolation, or as an alternative to, or a substitute for operating expenses or other financial statement data presented in accordance with GAAP in our consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">Rhythm has not provided a quantitative reconciliation of forecasted Non-GAAP Operating Expenses to forecasted GAAP operating expenses because the Company is unable, without making unreasonable efforts, to calculate the reconciling item, stock-based compensation expenses, with confidence. This item, which could materially affect the computation of forward-looking GAAP operating expenses, is inherently uncertain and depends on various factors, some of which are outside of Rhythm&#39;s control.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Corporate Contact:</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;">David Connolly</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;">Head of Investor Relations and Corporate Communications</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;">Rhythm Pharmaceuticals, Inc.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;">857-264-4280</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><font style="font-size:11pt;">dconnolly@rhythmtx.com</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Media Contact:</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;">Sheryl Seapy</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;">Real Chemistry</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;">(949) 903-4750</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;margin:0pt;"><font style="font-size:11pt;">sseapy@realchemistry.com</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Condensed Consolidated Balance Sheets</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(in thousands, except share and per share data)</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(Unaudited)</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:101.61%;"><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:15.73%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:14.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">    </font><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:15.73%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">    </font><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:14.82%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Current assets:</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">  </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">  </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Cash and cash equivalents</font></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">$</font></p></td><td style="vertical-align:bottom;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 106,095</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">$</font></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 89,137</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Short-term investments</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 208,393</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 231,428</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Accounts receivable, net</font></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 17,825</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 18,512</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Inventory</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 19,316</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 18,741</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Prepaid expenses and other current assets</font></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 17,659</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 16,382</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Total current assets</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 369,288</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 374,200</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Property and equipment, net</font></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 462</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 632</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Right-of-use asset</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 3,367</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 3,477</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Intangible assets, net</font></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 5,960</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 6,174</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Restricted cash</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 464</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 464</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Other long-term assets</font></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 7,144</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 7,326</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Total assets</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">$</font></p></td><td style="vertical-align:bottom;width:12.11%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 386,685</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">$</font></p></td><td style="vertical-align:bottom;width:12.85%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 392,273</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;">Liabilities, Convertible Preferred Stock and Stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">  </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">  </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Current liabilities:</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">  </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">  </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Accounts payable</font></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">$</font></p></td><td style="vertical-align:bottom;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 11,912</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">$</font></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 12,328</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Accrued expenses and other current liabilities</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 59,314</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 62,658</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Other current liability - LG Chem</font></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 38,783</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 37,704</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Lease liability</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 224</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Deferred revenue</font></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 1,286</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Deferred royalty obligation, current</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 1,590</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 1,541</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Total current liabilities</font></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 111,823</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 115,517</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Long-term liabilities:</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">  </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">  </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Deferred royalty obligation</font></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 107,934</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 108,269</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Lease liability, non-current</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 3,839</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 3,938</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Total liabilities</font></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 223,596</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 227,724</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Commitments and contingencies (Note 13)</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;">Series A convertible preferred stock, $0.001 par value: 150,000 shares authorized; 150,000 and 0 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively.  Liquidation preference of $150,000 as of March 31, 2025.</font></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 144,142</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 142,820</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Stockholders&#8217; equity:</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">  </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">  </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Preferred stock, $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2025 and December 31, 2024</font></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Common stock, $0.001 par value: 120,000,000 shares authorized; 63,494,892 and 62,390,654 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 62</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 61</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Additional paid-in capital</font></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">1,223,772</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 1,177,045</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Accumulated other comprehensive (loss)</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> (51)</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> (39)</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Accumulated deficit</font></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">(1,204,836)</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> (1,155,338)</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Total stockholders&#8217; equity</font></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.11%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 18,947</font></p></td><td style="vertical-align:bottom;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:12.85%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 21,729</font></p></td></tr><tr><td style="vertical-align:bottom;width:64.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Total liabilities, convertible preferred stock and stockholders&#8217; equity</font></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">$</font></p></td><td style="vertical-align:bottom;width:12.11%;background:#cceeff;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 386,685</font></p></td><td style="vertical-align:bottom;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.96%;background:#cceeff;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">$</font></p></td><td style="vertical-align:bottom;width:12.85%;background:#cceeff;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> 392,273</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;"><a name="OPERATIONSANDCOMPREHENSIVELOSS_760126"></a></font><b style="font-weight:bold;">Rhythm Pharmaceuticals, Inc.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;text-indent:36pt;margin:0pt;">Condensed Consolidated Statements of Operations and Comprehensive Loss</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.77%;"><tr><td style="vertical-align:bottom;width:60.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:36.38%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">    <font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:17.13%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    <font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:16.21%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Revenues:</p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Product revenue, net</p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 37,718</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 25,967</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">License revenue</p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (5,014)</font></p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 0.05pt 6pt;"><font style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Total revenues</p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 32,704</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 25,967</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Costs and expenses:</p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Cost of sales</p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 3,648</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 2,807</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 36,973</font></p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 128,665</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Selling, general, and administrative</p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 39,087</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 34,382</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Total costs and expenses</p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;background:#cceeff;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 79,708</font></p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;background:#cceeff;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 165,854</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (47,004)</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (139,887)</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (644)</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 524</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (5,409)</font></p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (4,755)</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 3,639</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 3,046</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Total other (expense), net</p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;background:#cceeff;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (2,414)</font></p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;background:#cceeff;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (1,185)</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (49,418)</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (141,072)</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 80</font></p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 300</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:14.62%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (49,498)</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:13.71%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (141,372)</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Accrued dividends on convertible preferred stock </p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (1,322)</font></p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;background:#cceeff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:14.62%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (50,820)</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:13.71%;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (141,372)</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:14.62%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.81)</font></p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:13.71%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (2.35)</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 63,059,165</font></p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 60,143,558</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive loss:</p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (50,820)</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (141,372)</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Foreign currency translation adjustment </p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (2)</font></p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (71)</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Unrealized (loss), net on marketable securities</p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:14.62%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (10)</font></p></td><td style="vertical-align:bottom;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.71%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (244)</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:14.62%;background:#cceeff;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (50,832)</font></p></td><td style="vertical-align:bottom;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;background:#cceeff;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:13.71%;background:#cceeff;border-bottom:3px double #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (141,687)</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rytm-20250507.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/6/2025 10:11:52 PM-->
<!--Modified on: 5/6/2025 10:11:52 PM-->
<xsd:schema targetNamespace="http://www.rhythmtx.com/20250507" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt="http://fasb.org/srt/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:rxp="http://xbrl.sec.gov/rxp/2024q3" xmlns:snj="http://xbrl.sec.gov/snj/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:cyd-8k-sub="http://xbrl.sec.gov/cyd-8k-sub/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024" xmlns:rytm="http://www.rhythmtx.com/20250507">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="rytm-20250507_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="rytm-20250507_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>rytm-20250507_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/6/2025 10:11:52 PM-->
<!--Modified on: 5/6/2025 10:11:52 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>rytm-20250507_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/6/2025 10:11:52 PM-->
<!--Modified on: 5/6/2025 10:11:52 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="rytm-20250507.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638821663127653828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638821663127653828" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638821663127653828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638821663127653828" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638821663127653828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638821663127653828" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638821663127653828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638821663127653828" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638821663127653828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638821663127653828" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638821663127653828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638821663127653828" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638821663127653828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638821663127653828" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638821663127653828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638821663127653828" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638821663127653828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638821663127653828" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638821663127653828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638821663127653828" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638821663127653828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638821663127653828" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638821663127653828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638821663127653828" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638821663127653828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638821663127653828" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638821663127653828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638821663127653828" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638821663127653828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638821663127653828" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638821663127653828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638821663127653828" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638821663127681410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638821663127681410" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638821663127681410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638821663127681410" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638821663127683777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638821663127683777" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638821663127683777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638821663127683777" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638821663127683777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638821663127683777" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638821663127683777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638821663127683777" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638821663127683777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638821663127683777" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  07,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RHYTHM PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-2159271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">222 Berkeley Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">12th Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">264-4280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RYTM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001649904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #,XIUI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( #,XIUJUA65P[P   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DDUJPS 01J]2M+?'LND/PO$FH:L6"@VT=">D
M22)B64*:8N?VE=7$H;0'*&BCF4]OWH!:Y85R 5^"\QC(8+R9;#]$H?R*'8B\
M (CJ@%;&,B6&U-RY8"6E:]B#E^HH]PAU5=V!19):DH096/B%R+I6*Z$"2G+A
MC-=JP?O/T&>85H ]6APH B\YL&Z>Z$]3W\(5,,,(@XW?!=0+,5?_Q.8.L'-R
MBF9)C>-8CDW.I1TXO#\_O>9U"S-$DH/"]"H:02>/*W:9_-:L-]M'UM55?5M4
MZ=QO.1<5%\W#Q^SZP^\J;)TV._./C2^"70N__D7W!5!+ P04    "  S.*=:
MF5R<(Q &  "<)P  $P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^O
MT'AG]FT+QC:!MK03<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\
M!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,
M7K5::0##.'W)$Q+#W(*+"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH
M0-!445IO7R"TY1\S^!7+5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;
M6"!_SF^GY$Y:B.%4PL3 :F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV
M?/;$[9^,RMIT-&T:X./Q>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJN
MD::JC5-/T_=]W^N;:)P*C5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G
M_:YKI.D6:$)&X^MZ$A6UY4#3( !8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)
M$?[&Q036:=(9EC1&<IV0!0X -\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U
M1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)
M\?LC6V&')VX[$W(Z'&="?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=
M]EA]]D]';B/7J<"S(M>41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&
M^+3&K!'@$WVWO@C(WXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\
MW*.76!4!EQC?-*HU+,76>)7 \:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:
M_IS30/"4+R3Z2I&/:;,CIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;
MLT8AA&F[\!ZO)(Z:K<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63
M/F#([,V1=<[6D0X1DEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX
M?H;5,VPLCO='U!=*Y \FIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z
M> HWEL:\4*Z">P'_T=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;
MQ/NN,=K7-"XH8U=RS<C'5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!
M)+C\B\KP*L0)Z&1;)0G+5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XL
MS_D\7^>TS0LS0[=R2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0C
MI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[
MY\%1L*/O/)8=QXCRHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4
MX&1@+: '@Z]1 O)256 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM
M(E(YPFF8$V>KRMYEL<%5'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*
MHO,94[[G*TG$53B_13.V$I<8O./FQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,
M"2Q;B%D2XDU=[=7GFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[
M2$R<><41 71% B.5' 86%S+D4.Z2D 83 <V4R43P H)DIAR F/H+O?(,N2D5
MSJT^.7]%+(.&3E[2)1(4BK ,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$]
M,W)#V%0E\Z[:)@N%V^)4S;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=S
MFWJXPD6L_UC6'ODRWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ
M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
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M>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ ,SBG6F60>9(9 0  SP,  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !
M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB
M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G
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M+GAM;%!+ 0(4 Q0    ( #,XIUJUA65P[P   "L"   1              "
M <,   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( #,XIUJ97)PC$ 8
M )PG   3              "  >$!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ ,SBG6OSXL-ER!   51$  !@              ("!(@@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( #,XIUJ?H!OPL0(
M .(,   -              "  <H,  !X;"]S='EL97,N>&UL4$L! A0#%
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  "H4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="rytm-20250507x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>rytm-20250507.xsd</File>
    <File>rytm-20250507_lab.xml</File>
    <File>rytm-20250507_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="rytm-20250507x8k.htm">rytm-20250507x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "rytm-20250507x8k.htm": {
   "nsprefix": "rytm",
   "nsuri": "http://www.rhythmtx.com/20250507",
   "dts": {
    "schema": {
     "local": [
      "rytm-20250507.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "rytm-20250507_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rytm-20250507_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "rytm-20250507x8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rytm-20250507x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rytm-20250507x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Adress Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.rhythmtx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001558370-25-006602-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-006602-xbrl.zip
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M49A)WM=0GOM_=0G_1W(^"@F'S*UG:1H9\B43L!GRL!S'FU>91.?T0G)8K4O
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M$\&PK5<)/^<%I,S2[LV'2D6!ZJ\LJ#P1L7'@V[$5L4#<"B\6;!#X(W;C^GV
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MMA*ROG:BO+JPN@VO02D60<->!^OM/<5W':RWWX)&^Q)7/D+6WL3R2A'M1"G
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M+GAS9%!+ 0(4 Q0    ( #,XIUJE;="?@04  (8^   5              "
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:+FAT;5!+!08     !0 % $T!  "T6P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>rytm-20250507x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rytm-20250507.xsd" xlink:type="simple"/>
    <context id="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649904</identifier>
        </entity>
        <period>
            <startDate>2025-05-07</startDate>
            <endDate>2025-05-07</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Tc_9O_02z6gHEm9BfBTDa9u5A_2_1">0001649904</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Tc_7qKdcS9CbECfe8iwelMl4A_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Narr_z6QW5g85E0Ky2mZQZjkEOQ">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Narr_5_ltw3aXGkeUdfohllrkng">2025-05-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Narr_BXS1KV24KE6SkUEVGzq01g">RHYTHM PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Tc_mcdMqPCO4k-zhT0dbLySvQ_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Tc_jmZNy_5G506ze2wRHzg7dw_0_2">001-38223</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Tc_wdOEX_W7QkCwqtrVPLGZMA_0_4">46-2159271</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Narr_j00hizaKnUmellr58-p8Gg">222 Berkeley Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Narr_vc6HyEUYGkO1E9t8o0LFvw">12th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Narr_IqbhZqGIq0G5KtCai2l_MA">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Narr_UQQTdYDXWk6WHZjnS7y6GA">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Narr_zTNLCF3dxEW8ylSItbB0wQ">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Narr_5taFRDHsHkaHsnhiqQZ0qA">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Narr_73wo20p600Kx6cAN-J_3UQ">264-4280</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Narr_NUr9-ew96k2vEh-S1nGJYQ">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Narr_1WwEAAvvLU2drqMjL8fXMg">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Narr_vDhae_m_e0u7dgMUGZdCqg">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Narr_eYC4BXG_BUWWcIsa0sGkDA">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Tc_K1YPFtmv_0qgTH83a6INyA_1_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Tc_ao2ncnMTOUex6aPLvWYFGQ_1_1">RYTM</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Narr_lV8hFqhSO0OD8_VT6jQBuA">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_5_7_2025_To_5_7_2025_yPkGhktK0EGy6YLwYtAf8g"
      id="Narr_iWD5zC-oGE-6sEAzhuum9Q">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
